Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

OBJECTIVE: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. METHODS: Retrospective health care record of 61 consecutive HIV treatment-naive...

Descripción completa

Detalles Bibliográficos
Autores principales: Waqas, Sarmad, O’Connor, Mairead, Levey, Ciara, Mallon, Paddy, Sheehan, Gerard, Patel, Anjali, Avramovic, Gordana, Lambert, John S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084612/
https://www.ncbi.nlm.nih.gov/pubmed/27826447
http://dx.doi.org/10.1177/2050312116675813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084612/
https://www.ncbi.nlm.nih.gov/pubmed/27826447
http://dx.doi.org/10.1177/2050312116675813

Ejemplares similares